Core Viewpoint - Aibo Medical (688050) reported a revenue of 787 million yuan for the first half of 2025, reflecting a year-on-year growth of 14.72%, with a net profit attributable to shareholders of 213 million yuan, up 2.53% [1] Revenue Breakdown - The revenue from surgical treatment products, particularly intraocular lenses, increased by 8.23%, with high-end products like "All-View" multifocal intraocular lenses and "Longjing" intraocular lenses showing rapid growth and an increasing market share [1] - The revenue from myopia control products, specifically the "Punotong" corneal reshaping lenses, grew by 5.63%, indicating sustained sales growth despite intensified competition and consumer downgrade [1] - In the vision care segment, revenue from contact lenses surged by 28.89%, primarily due to the company's efforts in expanding its self-owned brand sales channels [1]

格隆汇8月27日丨爱博医疗(688050.SH)发布2025半年度报告显示，公司上半年实现营业收入7.87亿元， 同比增长14.72%；归母净利润2.13亿元，同比增长2.53%；扣非归母净利润2.04亿元，同比增长2.63%。 ...

Company Overview - Aibono Medical achieved total revenue of CNY 786,691,059.79 in the first half of 2025, representing a year-on-year increase of 14.72% [1] - The net profit attributable to shareholders was CNY 213,309,113.88, reflecting a growth of 2.53% compared to the same period last year [1] - The company’s total assets reached CNY 3,932,898,062.92, marking a 12.47% increase from the previous year [1] Financial Performance - The gross revenue from surgical treatment products, particularly artificial lenses, grew by 8.23%, with high-end products like "All-View" multifocal lenses seeing rapid growth [1] - Revenue from myopia control products, specifically the "Puno Tong" orthokeratology lenses, increased by 5.63%, indicating sustained sales growth despite market challenges [1] - The revenue from contact lenses surged by 28.89%, attributed to the expansion of the company's proprietary brand sales channels [1] Profitability Metrics - The total profit for the period was CNY 241,557,499.33, a slight increase of 2.12% year-on-year [1] - The basic earnings per share rose by 1.82% to CNY 1.12, while the diluted earnings per share also increased by the same percentage [1] - The net cash flow from operating activities was CNY 154,143,662.19, up 26.43%, which is higher than the net profit growth [1] Research and Development - The total R&D expenditure was CNY 83,381,855.90, representing a year-on-year increase of 21.55%, accounting for 10.60% of total revenue [1] Shareholder Information - The total number of shareholders as of the report date was 15,408 [1]

Core Viewpoint - The company, Aibo Medical, is set to hold a half-year performance briefing on September 4, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in Q&A sessions [1]. Group 1: Meeting Details - The performance briefing will take place on September 4, 2025, from 11:00 to 12:00 [1]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [1]. - Investors can submit questions from August 28 to September 3, 2025, before the meeting [1]. Group 2: Participants - Key participants include the Chairman and General Manager, Mr. Xie Jiangbing, the Vice General Manager and CFO, Mr. Guo Yanchang, the Board Secretary, Ms. Zhou Yuqian, and Independent Director, Mr. Li Xunhu [1]. Group 3: Investor Participation - Investors can join the meeting online through the Shanghai Stock Exchange Roadshow Center on the scheduled date [1]. - Questions can be submitted via the Roadshow Center's website or through the company's investor email [1]. Group 4: Contact Information - The contact department for inquiries is the Securities Legal Affairs Department of Aibo Medical, with a provided phone number and email address for investor communication [1].

Fundraising Overview - The company raised a total of RMB 284,614,308.00, with a net amount of RMB 280,612,310.30 after deducting issuance costs [1][2] - As of June 30, 2025, the balance of the special account for raised funds was RMB 231,078,223.02 [1][2] Fund Management - The company has implemented strict management and usage protocols for the raised funds, adhering to relevant regulations and internal guidelines [1][4] - A tripartite supervision agreement was signed with the sponsor and the bank managing the special account [1][3] Fund Usage - A total of RMB 49,576,527.16 was invested in fundraising projects during the reporting period, with no changes in the purpose of the raised funds [2][4] - The company has not experienced any significant changes in the feasibility of the fundraising projects [2][4] Cash Management - The company has not used any temporarily idle raised funds for cash management during the reporting period [3][4] - A resolution was passed to allow the use of temporarily idle funds for cash management, but as of June 30, 2025, the balance for such management was RMB 0.00 [3][4] Loan to Subsidiary - The company approved a loan of up to RMB 26,000,000.00 to its subsidiary, Jiangsu Tianyan Medical Technology Co., Ltd., for project implementation [3][4] Compliance and Disclosure - The company has complied with all relevant laws and regulations regarding the use of raised funds and has disclosed the usage status in a timely manner [4]

Core Viewpoint - The report outlines the progress and evaluation of the "Quality Improvement and Efficiency Enhancement Action Plan" for 2025, emphasizing the company's commitment to high-quality development and investor value enhancement. Group 1: Business Performance - The company achieved operating revenue of 786.69 million yuan in the first half of the year, representing a year-on-year growth of 14.72% [1] - The net profit attributable to shareholders was 213.31 million yuan, with a year-on-year increase of 2.53% [2] - The revenue from surgical treatment products, particularly high-end artificial lenses, grew by 8.23%, while revenue from contact lenses increased by 28.89% due to expanded sales channels [1][2] Group 2: Market Expansion and Product Structure - The company has established an overseas sales network covering Europe, Asia, and South America, enhancing its market competitiveness [2] - The company is actively participating in international industry conferences and promotional activities to strengthen recognition among overseas doctors and patients [2] - The company has launched a new silicone hydrogel contact lens, breaking the monopoly of foreign companies in the Chinese market [3] Group 3: Quality Management and Production Capacity - The company has implemented a comprehensive quality control system to prevent potential issues in products and processes [2] - A special team has been formed to optimize the automated production line for contact lenses, aiming to increase production capacity significantly [3] - The company plans to achieve an annual production capacity of 252 million contact lenses and 500 million sets of molds after the completion of new projects [3] Group 4: Innovation and R&D - R&D investment increased by 21.55% year-on-year, accounting for 10.60% of operating revenue, supporting the development of new products and technologies [3][4] - The company applied for 44 patents during the reporting period, with 26 patents granted, enhancing its technological competitiveness [4] - The company is focusing on developing core technologies and protecting intellectual property to maintain its industry leadership [4] Group 5: Governance and Information Disclosure - The company has revised its governance documents to align with new regulations, enhancing its governance structure [6] - The board of directors has been re-elected to ensure continuity and diversity in decision-making [6] - The company emphasizes high-quality information disclosure to improve transparency and investor trust [7] Group 6: Shareholder Returns - The company has distributed cash dividends totaling 241 million yuan since its listing, reflecting its commitment to shareholder returns [8] - A share buyback program has been initiated, with 142,800 shares repurchased at an average price of 140.36 yuan per share [8] - The company aims to explore mechanisms that balance immediate and long-term shareholder interests [8]

（网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 28 日（星期四）至 9 月 3 日（星期三）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司投资者邮箱 （investors@ebmedical.com）进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 爱博诺德（北京）医疗科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 爱博诺德（北京）医疗科技股份有限公司（以下简称"爱博医疗"或"公司"） 已于 2025 年 8 月 28 日在上海证券交易所网站（www.sse.com.cn）发布了公司《2025 年半年度报告》。为便于广大投资者更全面深入地了解公司 2025 年半年度经营成 果、财务状况，公司计划于 9 月 4 日（星期四）11:00-12:00 举行 2025 年半年度业 绩说明会（以下简称"说明会"），就投资者普 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-047 爱博诺德（北京）医疗科技股份有限公司 2025 年半年度募集资金存放与实际使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）募集资金金额及到位时间 根据中国证券监督管理委员会出具的《关于同意爱博诺德（北京）医疗科技 股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕774 号）， 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"或"本公司"） 2024 年度以简易程序向特定对象发行人民币普通股 3,593,615 股，每股发行价格 79.20 元 ， 募 集 资 金 总 额 284,614,308.00 元 ， 扣 除 相 关 发 行 费 用 人 民 币 4,001,997.70 元后，实际募集资金净额为人民币 280,612,310.30 元。2025 年 4 月 29 日，信永中和会计师事务所（特殊普通合伙）对本次发行募集资金到位情况进 行了审验，并出具了《爱博诺德（北京）医疗科技股份 ...

爱博诺德（北京）医疗科技股份有限公司 关于 2025 年度"提质增效重回报"行动方案的 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》等相关要求， 爱博诺德（北京）医疗科技股份有限公司（以下简称"爱博医疗"或"公司"）积 极践行"以投资者为本"的上市公司发展理念，推动公司高质量发展和投资价值提 升，已于 2025 年 4 月 23 日披露了《2025 年度"提质增效重回报"行动方案》（以 下简称"《行动方案》"）。 2025 年上半年，公司积极落实《行动方案》中的各项工作，聚焦主营业务发展、 推动创新研发成果转化、强化投资者关系管理，有效传递公司长期投资价值。现将 《行动方案》半年度实施进展及评估情况报告如下： 一、聚焦主业，推动高质量发展 2025 年上半年，公司经营成果取得如下进展： （一）夯实主营业务，经营业绩持续增长 面对复杂多变的国内外形势，公司稳健经营，上半年实现营业收入 78,669.11 万 元，同比增长 14.72%。手术治疗产品中，人工晶状体营业收入同比增长 8.23%，"全 视"多焦人工晶状体、"龙晶"有晶体眼人工晶状体等高端产品增长迅速，占比不断 提升；近视防控产品中，"普诺 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月27日，爱博医疗发布公告称，2025年上半年实现营业 收入7.87亿元，同比增长14.72%；归属于上市公司股东的净利润为2.13亿元，同比增长2.53%；归属于 上市公司股东的扣除非经常性损益的净利润为2.04亿元，同比增长2.63%。 ...